![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: SMG9 |
Gene summary for SMG9 |
![]() |
Gene information | Species | Human | Gene symbol | SMG9 | Gene ID | 56006 |
Gene name | SMG9 nonsense mediated mRNA decay factor | |
Gene Alias | C19orf61 | |
Cytomap | 19q13.31 | |
Gene Type | protein-coding | GO ID | GO:0000184 | UniProtAcc | A0A024R0Q0 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
56006 | SMG9 | LZE7T | Human | Esophagus | ESCC | 7.88e-04 | 2.77e-01 | 0.0667 |
56006 | SMG9 | LZE24T | Human | Esophagus | ESCC | 1.26e-08 | 1.78e-01 | 0.0596 |
56006 | SMG9 | P1T-E | Human | Esophagus | ESCC | 5.87e-10 | 3.74e-01 | 0.0875 |
56006 | SMG9 | P2T-E | Human | Esophagus | ESCC | 8.34e-13 | 2.47e-01 | 0.1177 |
56006 | SMG9 | P4T-E | Human | Esophagus | ESCC | 1.14e-09 | 1.81e-01 | 0.1323 |
56006 | SMG9 | P5T-E | Human | Esophagus | ESCC | 1.46e-07 | 1.18e-01 | 0.1327 |
56006 | SMG9 | P8T-E | Human | Esophagus | ESCC | 9.57e-25 | 4.21e-01 | 0.0889 |
56006 | SMG9 | P9T-E | Human | Esophagus | ESCC | 5.59e-09 | 1.41e-01 | 0.1131 |
56006 | SMG9 | P10T-E | Human | Esophagus | ESCC | 3.14e-31 | 4.80e-01 | 0.116 |
56006 | SMG9 | P11T-E | Human | Esophagus | ESCC | 1.20e-11 | 3.87e-01 | 0.1426 |
56006 | SMG9 | P12T-E | Human | Esophagus | ESCC | 1.15e-15 | 3.05e-01 | 0.1122 |
56006 | SMG9 | P15T-E | Human | Esophagus | ESCC | 6.83e-20 | 2.69e-01 | 0.1149 |
56006 | SMG9 | P16T-E | Human | Esophagus | ESCC | 6.30e-15 | 2.94e-01 | 0.1153 |
56006 | SMG9 | P17T-E | Human | Esophagus | ESCC | 2.82e-02 | 2.43e-01 | 0.1278 |
56006 | SMG9 | P20T-E | Human | Esophagus | ESCC | 3.48e-07 | 2.72e-01 | 0.1124 |
56006 | SMG9 | P21T-E | Human | Esophagus | ESCC | 3.16e-07 | 1.20e-01 | 0.1617 |
56006 | SMG9 | P22T-E | Human | Esophagus | ESCC | 1.49e-10 | 1.61e-01 | 0.1236 |
56006 | SMG9 | P23T-E | Human | Esophagus | ESCC | 2.73e-17 | 3.72e-01 | 0.108 |
56006 | SMG9 | P24T-E | Human | Esophagus | ESCC | 2.78e-13 | 1.95e-01 | 0.1287 |
56006 | SMG9 | P26T-E | Human | Esophagus | ESCC | 5.47e-24 | 4.05e-01 | 0.1276 |
Page: 1 2 3 4 5 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0006401110 | Esophagus | ESCC | RNA catabolic process | 204/8552 | 278/18723 | 3.39e-21 | 5.66e-19 | 204 |
GO:0034655110 | Esophagus | ESCC | nucleobase-containing compound catabolic process | 272/8552 | 407/18723 | 2.92e-18 | 2.90e-16 | 272 |
GO:0006402110 | Esophagus | ESCC | mRNA catabolic process | 170/8552 | 232/18723 | 8.70e-18 | 8.00e-16 | 170 |
GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
GO:004670018 | Esophagus | ESCC | heterocycle catabolic process | 286/8552 | 445/18723 | 1.12e-15 | 7.47e-14 | 286 |
GO:004427019 | Esophagus | ESCC | cellular nitrogen compound catabolic process | 288/8552 | 451/18723 | 3.03e-15 | 1.79e-13 | 288 |
GO:001943918 | Esophagus | ESCC | aromatic compound catabolic process | 295/8552 | 467/18723 | 1.09e-14 | 5.98e-13 | 295 |
GO:190136118 | Esophagus | ESCC | organic cyclic compound catabolic process | 307/8552 | 495/18723 | 9.99e-14 | 4.80e-12 | 307 |
GO:000095618 | Esophagus | ESCC | nuclear-transcribed mRNA catabolic process | 88/8552 | 112/18723 | 9.41e-13 | 4.14e-11 | 88 |
GO:000018414 | Esophagus | ESCC | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 32/8552 | 37/18723 | 2.96e-07 | 4.23e-06 | 32 |
GO:004427021 | Liver | HCC | cellular nitrogen compound catabolic process | 303/7958 | 451/18723 | 9.76e-27 | 3.64e-24 | 303 |
GO:004670021 | Liver | HCC | heterocycle catabolic process | 299/7958 | 445/18723 | 2.07e-26 | 7.29e-24 | 299 |
GO:190136121 | Liver | HCC | organic cyclic compound catabolic process | 325/7958 | 495/18723 | 6.52e-26 | 2.18e-23 | 325 |
GO:001943921 | Liver | HCC | aromatic compound catabolic process | 309/7958 | 467/18723 | 1.56e-25 | 4.94e-23 | 309 |
GO:000640121 | Liver | HCC | RNA catabolic process | 201/7958 | 278/18723 | 3.88e-24 | 1.02e-21 | 201 |
GO:003465521 | Liver | HCC | nucleobase-containing compound catabolic process | 273/7958 | 407/18723 | 4.84e-24 | 1.23e-21 | 273 |
GO:000640221 | Liver | HCC | mRNA catabolic process | 169/7958 | 232/18723 | 4.50e-21 | 6.96e-19 | 169 |
GO:000095621 | Liver | HCC | nuclear-transcribed mRNA catabolic process | 84/7958 | 112/18723 | 2.54e-12 | 1.18e-10 | 84 |
GO:000170111 | Liver | HCC | in utero embryonic development | 204/7958 | 367/18723 | 2.44e-07 | 4.30e-06 | 204 |
GO:000018411 | Liver | HCC | nuclear-transcribed mRNA catabolic process, nonsense-mediated decay | 29/7958 | 37/18723 | 9.37e-06 | 1.09e-04 | 29 |
Page: 1 2 3 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SMG9 | SNV | Missense_Mutation | c.1400A>G | p.Gln467Arg | p.Q467R | Q9H0W8 | protein_coding | tolerated(0.31) | benign(0.011) | TCGA-AO-A128-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD | |
SMG9 | SNV | Missense_Mutation | novel | c.608A>G | p.Asp203Gly | p.D203G | Q9H0W8 | protein_coding | deleterious(0.02) | probably_damaging(0.958) | TCGA-BH-A42T-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SMG9 | SNV | Missense_Mutation | rs200906288 | c.743N>A | p.Arg248Gln | p.R248Q | Q9H0W8 | protein_coding | tolerated(0.51) | benign(0.186) | TCGA-DS-A1OB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | carboplatin | PD |
SMG9 | SNV | Missense_Mutation | c.860N>A | p.Arg287His | p.R287H | Q9H0W8 | protein_coding | deleterious(0.01) | possibly_damaging(0.714) | TCGA-A6-6781-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | oxaliplatin | SD | |
SMG9 | SNV | Missense_Mutation | novel | c.1549N>A | p.Arg517Ser | p.R517S | Q9H0W8 | protein_coding | deleterious(0) | probably_damaging(0.978) | TCGA-AA-3496-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
SMG9 | SNV | Missense_Mutation | c.38N>T | p.Gly13Val | p.G13V | Q9H0W8 | protein_coding | deleterious_low_confidence(0) | probably_damaging(0.998) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SMG9 | SNV | Missense_Mutation | rs568897261 | c.367N>A | p.Ala123Thr | p.A123T | Q9H0W8 | protein_coding | tolerated(0.47) | benign(0) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
SMG9 | SNV | Missense_Mutation | c.986N>A | p.Ser329Asn | p.S329N | Q9H0W8 | protein_coding | tolerated(1) | benign(0.003) | TCGA-AZ-4681-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
SMG9 | SNV | Missense_Mutation | novel | c.820N>A | p.Leu274Met | p.L274M | Q9H0W8 | protein_coding | tolerated(0.11) | probably_damaging(0.943) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
SMG9 | SNV | Missense_Mutation | novel | c.926N>T | p.Ala309Val | p.A309V | Q9H0W8 | protein_coding | deleterious(0) | possibly_damaging(0.824) | TCGA-A5-A2K7-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD |
Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |